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ABSTRACT
Gene transcription in a set of 49 human primary lung
adenocarcinomas and 9 normal lung tissue samples
was examined using Affymetrix GeneChip tech-
nology. A total of 3442 genes, called the set MAD,
were found to be either up- or down-regulated by
at least 2-fold between the two phenotypes. Genes
assigned to a particular gene ontology term were
found, in many cases, to be significantly unevenly
distributed between the genes in and outside MAD.
Terms that were overrepresented in MAD included
functions directly implicated in the cancer cell
metabolism. Based on their functional roles and
expression profiles, genes in MAD were grouped
into likely co-regulated gene sets. Highly conserved
sequences in the 5 kb region upstream of the genes
in these sets were identified with the motif discovery
tool, MoDEL. Potential oncogenic transcription fac-
tors and their corresponding binding sites were
identified in these conserved regions using the
TRANSFAC 8.3 database. Several of the transcrip-
tion factors identified in this study have been
shown elsewhere to be involved in oncogenic pro-
cesses. This study searched beyond phenotypic
gene expression profiles in cancer cells, in order
to identify the more important regulatory transcrip-
tion factors that caused these aberrations in gene
expression.
INTRODUCTION
The transformation of normal lung tissue into lung adenocar-
cinomas involves, among other characteristic features, a hall-
mark process by which the cell loses control of its replication
process (an accelerated cell cycle) (1). Adenocarcinomas have
a high incidence of fatality in patients in US, and a similar
trend is developing in other countries (2). At present, lung
cancer studies generally incorporate two main objectives: pro-
viding an early and sensitive diagnosis, and trying to under-
stand the molecular basis underlying the disease formation.
Recently, the availability of the human genome sequence (3)
and gene expression proﬁling techniques (4) have provided
new insights, narrowing the gap to achieve these objectives.
The challenges that lie ahead include systematically identify-
ingthefunctionsofallcancerassociatedgenes,andcontinuing
the efforts todecipher their regulatorynetworks. This informa-
tion will provide a much deeper understanding of the mech-
anism of cancer cell formation and development, and assist
in the identiﬁcation of potent therapeutic targets for disease
control and eradication.
Computationalmethodsthatareemployedtoidentifycancer
associated genes from megabytes of noisy microarray data
still require further development. Data normalization proced-
ures may have an important effect on the succeeding down-
stream data analysis (5–8). Using human housekeeping genes
as the least variable set of gene expression proﬁles is one
accepted method (9). Many computational methods have
been introduced to determine marker genes for cancer from
gene expression datasets (10,11). These methodologies aim to
stratify samples into tissue classes or phenotypes based on the
*To whom correspondence should be addressed at HKU-Pasteur Research Centre, 8, Sassoon Road, Pokfulam, HongKong, China. Tel: +852 2816 8438;
Fax: +852 2872 5782; Email: daniely@hkusua.hku.hk
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use permissions, please contact journals.permissions@oupjournals.org.
ª 2005, the authors
Nucleic Acids Research, Vol. 33 No. 1 ª Oxford University Press 2005; all rights reserved
Nucleic Acids Research, 2005, Vol. 33, No. 1 409–421
doi:10.1093/nar/gki188
  Published online January 14, 2005ability of sets of differentially regulated genes to discriminate
among the samples. Methods such as recursive partitioning
(12), expression ratio analysis (13), principal component ana-
lysis (14), partial least squares (15), and independent compon-
ent analysis (16)have been usedtoidentify theminimumsetof
genes that can achieve this classiﬁcation. However, the usually
small number (tens) of (tissue) samples per class and the large
number (tens of thousands) of features (genes) in these data-
setscast doubt on the statistical signiﬁcance ofgenes identiﬁed
as discriminating between normal or cancer tissues or cancer
subtypes. The effects on the detection of cancer marker genes
due to these constraints, which can lead to genes being
classiﬁed as markers by chance, have been investigated (17).
Recently, the use of computational methods to identify reg-
ulatory elements has become increasingly important (18). This
is partly because the alternative of experimental determination
of cis-regulatory elements can be inaccurate, and is often slow
and laborious (19). A common way to analyze regulatory
relationships among genes using microarray data is to cluster
the genes, based on their expression proﬁles, into sets of puta-
tively co-regulated genes. This assumes that co-regulated
genes are likely to have cis-regulatory elements in common
(20). However, searching for common sequence signals in
genomic regions near these genes can lead to the detection
of spurious cis-regulatory elements, as many genes may show
similar expression proﬁles for reasons other than co-regulation
(20). Many studies have shown that biologically relevant cis-
regulatory elements often occur in groups (21,22). Following
this rationale, conserved regulatory motifs correlated to gene
expressionwerediscoveredbyﬁttingalinearregressionmodel
to the expression arrays from Saccharomyces cerevisiae (23)
and an extension of this technique was used to identify binding
motifs of the transcription factors ROX1p and YAP1p (24). In
this work, we performed a microarray based study of a set of
normal lung tissues and a set of primary lung adenocarcino-
mas. Our aims were, ﬁrst, to distinguish the broadest set of
genes (MAD) that showed differential expression levels across
the two tissue types and investigate the correlation of their
gene expression proﬁles with the tissue type. Second, we
wished to examine the division of genes with the same func-
tional annotation between the MAD set and the remaining
genes on the microarray to ﬁnd functional groups dispropor-
tionately represented in MAD. Finally, we attempted to identify
the transcriptionfactors,aswellastheircorresponding binding
sites, which regulate the observed expression differences of
the genes in the MAD set.
The rationale for the ﬁrst two aims was that, we could make
use of the knowledge accumulated by scientists on genes in
the MAD set, by using functional annotations assigned through
Gene Ontology terms, to investigate the nature of the bio-
logicalprocessesthatwereactuallyperturbedincancercells.It
wasexpectedthatsomefunctionalclasseswouldpreferentially
befoundintheMADgene set.Instead ofclustering genes based
solely on their expression proﬁles, genes were ﬁrst selected by
sharing a gene ontology term and then clustered by an expres-
sion proﬁle. The reasoning behind this was that genes with the
same function and similar expression proﬁles were more likely
to be under the same regulatory control than genes with differ-
ing functions but similar expression proﬁles. ‘In biblio’ ana-
lysis of genes’ neighborhoods has been long advocated as an
efﬁcient means to permit inductive reasoning by using the
knowledge accumulated by the worldwide community of
researchers (25). A motif ﬁnding algorithm developed by us,
MoDEL (26), was used to discover highly conserved DNA
regions associated with the genes in a cluster, before these
sequences were scanned against the TRANSFAC 8.3 database
to detect plausible oncogenic transcription factor binding sites.
MATERIALS AND METHODS
Primary lung adenocarcinoma dataset
Tissue samples for the complete cohort of this study were
collected, with informed consent, by the Department of Patho-
logy, The University of Hong Kong, Queen Mary Hospital,
Pokfulam, Hong Kong. A total of 58 patients gave samples
with normal lung tissue (n = 9) and primary lung adenocarci-
nomas (n = 49). Identiﬁer code numbers were assigned to each
tissue sample and its correlated clinical data. The link between
the code numbers and all patient identiﬁers was destroyed,
rendering the samples and clinical data completely anonym-
ous. Clinical data from hospital records included the age and
sex of the patient, smoking history, type of resection, post-
operative pathological staging, post-operative histopatho-
logical diagnosis, patient survival information, time of last
follow-up interval or time of death (when known), and site
ofdisease recurrence (when known). Information for the entire
dataset is provided as Supplementary Material at http://
bioinfo.hku.hk/~daniely/lung_microarray/. It is noted that
the numbers do not always add to 58, as complete information
could not be found for all samples.
The gender composition of the cohort was 25 males and
33 females. The reported smoking history of the patients was
24 non-smokers, 10 smoking at least 40 packs per year, seven
ex-smokers and nine passive smokers. Post-operative patho-
logical staging of these samples revealed 26 stage I, 8 stage II,
14 stage III and 1 stage IV tumors.
Tissue samples were snap-frozen in liquid nitrogen within
30 min after dissection and kept at  70 C until use. Tumor
samples were examined before use to ensure at least 70% of
tumor by area. RNA was extracted following standard proto-
cols and hybridized to Affymetrix HG-U133A GeneChips.
Expression values from a total of 22 283 transcript probe
sets were collected using Affymetrix scanners and analysis
software (Microarray Suite 5.0.1). The raw dataset is publicly
available at ArrayExpress (public repository for micro-
array data www.ebi.ac.uk/arrayexpress; accession number:
E-MEXP-231) (27,28); or can be downloaded at http://
bioinfo.hku.hk/~daniely/lung_microarray/.
Data re-scaling and feature selection
The raw expression data from each sample was rescaled (nor-
malized) to account for systematic differences in signal inten-
sities among the microarrays, using standard procedures in
Affymetrix Microarray Suite 5.0.1. Expression values from
each microarray were multiplied by a scaling factor to
make the average intensity of a set of house keeping genes
on each microarray equal to an arbitrarily deﬁned target
intensity of 500.
To identify genes that are tissue phenotype related, the
mean expression level of all genes in normal tissues and in
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average expression levels of a gene between the two tissue
classesexceeded2-fold,thegeneswereincludedinthesetMAD.
Gene to tissue correlation
The tissue type distinction is represented by an idealized
expression pattern (a vector with size 1 · 58), in which the
expression is labeled uniformly high (value = 1) in adeno-
carcinoma tissue type and labeled uniformly low (value = 0)
in normal tissue class. Correlation coefﬁcients were cal-
culated for the comparison of this vector with the expression
proﬁles of each gene in MAD. The distribution of correlation
coefﬁcients was counted in bins of 0.2. The result was
compared to the corresponding distribution obtained for ten
random permutations of the idealized tissue labels to give
the average random correlation coefﬁcients for each gene
(Figure 1).
Determination of overrepresentation of gene ontology
terms in the set MAD
GeneOntology (http://www.geneontology.org/) terms, which
classify a gene according to its molecular function, biological
process, cellular component and chromosomal localization,
were collected for each gene on the Affymetrix HG-U133A
microarray from the Affymetrix library ﬁles. By using the
hypergeometric distribution (Equation 1), genes with each
of these functional annotations could be assessed to see if
they are overrepresented in the set MAD. Given G annotated
genes on a microarray, of which A have a certain function
(gene ontology term), and a set of k genes selected
independently of the functional annotations (MAD), the prob-
ability that n or more of the set of k genes have this function
can be calculated by Equation 1 (23). If the P-value of
observing the number of genes with a particular gene ontology
term in the set MAD was <0.001, the term was considered to
be signiﬁcantly overrepresented in the set MAD. DNA-Chip
Analyzer (dChip) (29) was used to perform this task.
p ¼
X min k‚A ½ 
i¼n
A
i
  
G A
k i
  
G
k
   1
Constructing gene relationship trees for
overrepresented gene ontology terms
For all possible combinations of gene pairs that belong to each
gene ontology term overrepresented in MAD the correlation
coefﬁcient, r, of their expression proﬁles was calculated. A
pairwise gene distance matrix Mdistance, using the distance 1-r
was formed for the genes. The neighbor-joining algorithm
(NJ) (30) was used to construct a gene relationship tree
from pairwise gene distance matrix. This was performed to
identify gene neighbors whose expression values followed a
common trend. The NJ algorithm is a special case of the star
decomposition method. Starting from a star tree, the ﬁnal
relationship tree is constructed systematically by linking the
least distant pair of nodes (genes in this case). The main
advantage of the algorithm is that it permits lineages with
largely different branch lengths. The programming script
Figure 1. Histogramofthecancerassociatedgenes(MAD)correlationtothetissuelabels(normalorlungadenocarcinomas).Theaveragehistogramsgeneratedfrom
10 separate random permutations of the cancer labels in the original lung adenocarcinoma dataset is also displayed.
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programming language and the tree was calculated using
MEGA2 (31).
Extraction of the upstream regions for putatively
co-regulated gene sets
Putatively co-regulated genes from each gene ontology term
that was overrepresented in MAD were selected in accordance
with two criteria: (i) a distance metric cutoff value (di,j < 0.20)
for all pairwise gene distances within the selected N members
of the gene set; and (ii) the minimum mean aggregated pair-
wisedistances[minðð1=
NC2Þ
P
i¼select_gene_in_GAT_j di‚jÞ]forthe
selected N members of the gene set. The rationale for choosing
these criteria was to ﬁnd a single most correlated gene cluster
that minimizes the total branch length di,j. For instance, if there
are two gene clusters (each constituted of four and ﬁve gene
members, respectively) in the tree topology found to be
satisfying criterion one, i.e. get sets in which all pairwise
gene distances (
4C2 = 6 and
5C2 = 10 distances, respectively)
satisfy the distance metric cutoff value <0.2, the ﬁnal gene set
selected should be the one with the minimum mean aggregated
pairwise distances (criterion two). As a result, a different
numbers of genes will be selected from each gene ontology
term based on these criteria. For each of the selected genes, the
corresponding 5 kb region located directly upstream of the
transcription start site was extracted as described previously
(32). Several sequence features including sequence gaps, con-
tinuity, consistency between the two distinct drafts of human
genomes (3,33,34) were taken into consideration. Detailed
information can be found in (32).
Identification of conserved regions and detection
of associated transcription factors
All 5 kb unaligned DNA sequences associated with each gene
ontology term group overrepresented in MAD, were searched
using MoDEL (26), to reveal possible highly conserved
DNA regions. MoDEL employs an evolutionary algorithm
and hill-climbing optimization for global and local explora-
tion of two targeted search spaces, respectively (all possible
words and all possible ungapped local multiple alignments).
This heuristic algorithm has been shown to have more efﬁ-
cient optimization capabilities than other motif discovery
tools (26). The word size was set to be 50 bp in the present
study because we found that the conserved regions identiﬁed
by MoDEL remained rather consistent with different sizes
of word or segment length. A 50 bp segment length (the
longest implemented in MoDEL) also allows a larger win-
dow, whereby the most conserved motifs can be captured
together with their less similar surrounding residues. The
information content for all conserved regions identiﬁed
was calculated based on the Kullback–Leibler divergence
(relative entropy).
All conserved regions identiﬁed by MoDEL were scanned
against all vertebrate transcription factor position weight
matrix proﬁles contained in the TRANSFAC database version
8.3 (35) to identify all previously known transcription binding
sites. To incorporate stronger matches of transcription factor
binding sites, stringent settings for the Match program (36)
were employed. Both the core matrix and overall matrix sim-
ilarity were required to be least 0.9 to be considered a match.
RESULTS
Selection of the cancer associated gene set MAD
A total of 3442 genes were found to be either up- or down-
regulated by more than 2-fold between the normal and adeno-
carcinoma tissue sets (Table 1). These genes formed the
cancer associated gene set MAD. Of these genes, 1294 showed
down-regulation and 2148 showed up-regulation of gene
expression levels in adenocarcinomas. At the extreme ends
of the fold change range, the receptor for advanced glycation
end product (RAGE) was found to be repressed by >32-fold in
adenocarcinomas while the D G antigen (GAGED2) was
found to be up-regulated by >128-fold. Real-time quantitative
RT–PCR analysis (Supplementary Materials) to verify the
mRNA transcript levels for carbonic anhydrase IV (CA4)
and RAGE were performed in 14 independent tissue samples
(seven samples from each tissue phenotype). The abundance
of mRNA transcripts for both genes was extremely low in the
adenocarcinoma samples. If a gene is not expressed or
expressed at very low levels in a sample, then fold change
values may become large due to the low denominator. Fold
change values must be considered in conjunction with expres-
sion levels.
Functional annotation groups significantly
overrepresented in MAD
Down- and up-regulated genes in MAD were treated separately
to detect functional annotation groups that may be overrep-
resented in adenocarcinoma associated genes. Tables 2 and 3,
respectively, give the gene ontology terms signiﬁcantly over-
represented (P < 0.001) in down- and up-regulated genes of
MAD. The tables give the number of genes with that gene
ontology term on the HG-U133A microarray, the number
found, and the P-value of ﬁnding at least that number of
genes (by random chance) in MAD.
For genes down-regulated in adenocarcinomas, several
gene ontology terms related to immune responses were
overrepresented, indicating that there appeared to be a depres-
sionindefensemechanismsingeneral,fortheadenocarcinoma
tissue samples (Table 2). In addition, genes associated with
‘signal transducer activity’ (e.g. TEK tyrosine kinase, G
protein-coupled receptor kinase) were also identiﬁed to be
signiﬁcantly overrepresented in down-regulated genes in
MAD, suggesting the blockage of signal transduction genes in
adenocarcinoma cells. Many gene ontology terms that were
overrepresented in the up-regulated genes of MAD were asso-
ciated with the cell cycle and cell replication machinery
(Table 3) as might be expected from accelerated cancer cell
proliferation.
Construction of relationship trees and determination
of putatively co-regulated genes
After obtaining the constituent member genes for each gene
ontology term overrepresented in MAD, we investigated their
pairwise gene expression relationships. Supplementary
Material ﬁgure 2 shows an example of such a study for the
412 Nucleic Acids Research, 2005, Vol. 33, No. 1gene ontology term ‘DNA replication and chromosomal cycle’
with the GenBank accession numbers for each tree branch
corresponding to the genes in MAD that are assigned this
ontology term. The branch distances displayed were used to
derive the putatively co-regulated gene set (marked by an
asterisk) according to the two criteria stated in the Materials
and Methods section. In this example, the putatively
co-regulated genes were: (i) MCM2–mini-chromosome main-
tenance deﬁcient 2; (ii) replication factor C (activator 1) 4; and
(iii) CDC45–cell division cycle 45-like.
Identification of conserved DNA motifs and
transcription factors associated with a GO term
Conserved regions, within 5 kb of the transcription start
site, of the putatively co-regulated genes associated with
each gene ontology term overrepresented in MAD were iden-
tiﬁed using MoDEL (30). Example results from four gene
ontology terms: (i) DNA replication and chromosomal
cycle; (ii) nuclear division; (iii) cellular defense response
and (iv) signal transduction, are shown in Table 4. The ﬁrst
two terms are associated with genes that were up-regulated in
adenocarcinoma tissues, whereas the latter two terms are asso-
ciated with down-regulated genes. Conserved regions are pre-
sented using IUPAC uncertainty codes, with highly conserved
residues shown in bold, along with their start position relative
to the transcription start site. The occurrence of each of these
50mers in regions 5 kb upstream of all human genes (32) is
shown along with the proportion of those genes that have the
same GO term and regulation pattern of the gene in the table.
The ﬁnal column reports the transcription factors (from
TRANSFAC 8.3) that may bind to the conserved region
based on matches to their binding site motifs. The complete
data for Table 4 can be found at http://bioinfo.hku.hk/
~daniely/lung_microarray/.
Table 1. Genes that were identified to be down- or up-regulated in adenocarcinomas
Gene description (Gene down-regulated in lung AD) Probe set Fold
log(AD/N)
Mean expression
for normal lung
Mean expression
for AD lung
Consensus sequence for Homo sapiens mRNA for receptor
for Advanced Glycation End Product (RAGE)
217046_s_at  5.523 942.82 20.51
Homo sapiens fatty acid binding protein 4, adipocyte (FABP4) 203980_at  4.768 3365.42 123.48
Human alpha-globin gene with flanks 217414_x_at  4.419 9787.41 457.42
Homo sapiens mRNA; cDNA DKFZp564N0582 (from clone
DKFZp564N0582)
209074_s_at  4.294 678.28 34.58
Homo sapiens carbonic anhydrase IV (CA4) 206208_at  4.276 275.78 14.24
Homo sapiens RAGE mRNA for advanced glycation endproducts
receptor, whole CDS
210081_at  4.261 1593.08 83.06
Homo sapiens ficolin (collagen fibrinogen domain-containing)
3 (Hakata antigen) (FCN3)
205866_at  4.166 1790.33 99.70
Human sickle cell beta-globin mRNA 209116_x_at  4.155 14733.26 827.29
Consensus includes gb:BF939489 209469_at  4.028 330.68 20.27
Homo sapiens hemoglobin, gamma A (HBG1) 204848_x_at  3.922 264.79 17.47
Homo sapiens adipose specific 2 (APM2) 203571_s_at  3.898 3042.43 204.08
Homo sapiens hypothetical protein FLJ10970 (FLJ10970) 219230_at  3.884 1521.30 103.06
Consensus includes gb:T50399/UG=Hs.251577 hemoglobin, alpha 1 214414_x_at  3.874 13447.88 917.38
Homo sapiens colony stimulating factor 3 (granulocyte) (CSF3) 207442_at  3.873 145.31 9.92
Homo sapiens mutant beta-globin (HBB) gene 217232_x_at  3.864 15087.91 1036.22
Gene description (Gene up-regulated in lung AD) Probe Set Fold log(AD/N)
Homo sapiens XAGE-1 protein (XAGE-1) 220057_at 7.311 4.79 760.58
Human alpha-1 type XI collagen (COL11A1) 37892_at 6.208 6.10 451.07
Consensus includes gb:AI697108;/UG=Hs.102482 mucin 5,
subtype B, tracheobronchial
213432_at 6.192 4.84 354.11
Homo sapiens dipeptidyl peptidase IV (DPP4) 203716_s_at 5.932 6.81 415.78
Consensus includes gb:AU159942;/UG=Hs.156346
topoisomerase (DNA) II alpha (170 kDa)
201291_s_at 5.620 3.24 159.61
Homo sapiens serine protease inhibitor, Kazal type 1
(SPINK1);/UG=Hs.181286 serine protease inhibitor, Kazal type 1
206239_s_at 5.274 51.74 2002.30
Consensus includes gb:X98568;/UG=Hs.179729 collagen,
type X, alpha 1 (Schmid metaphyseal chondrodysplasia)
217428_s_at 4.991 21.98 698.84
Consensus includes gb:AW192795;/UG=Hs.103707 apomucin 214303_x_at 4.969 5.26 164.65
Human nephropontin mRNA;/UG=Hs.313 secreted phosphoprotein 1
(osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
209875_s_at 4.851 121.29 3499.34
Homo sapiens matrix metalloproteinase 1 (interstitial collagenase) (MMP1) 204475_at 4.806 25.07 701.09
Homo sapiens neuromedin U (NMU) 206023_at 4.776 5.80 158.88
Homo sapiens cytokine receptor-like factor 1 (CRLF1) 206315_at 4.737 14.22 379.16
Homo sapiens, serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 3
209720_s_at 4.597 2.13 51.63
Homo sapiens multidrug resistance-associated protein homolog MRP3
(MRP3);/UG=Hs.90786 ATP-binding cassette, sub-family
C (CFTRMRP), member 3
209641_s_at 4.570 14.73 350.01
Consensus includes gb:BE791251;/UG=Hs.25640 claudin 3 203953_s_at 4.462 6.82 150.39
The description of each gene, its probe set in HG-U133A GeneChip and log fold change are given in the table. The complete table can be downloaded at http://
bioinfo.hku.hk/~daniely/lung_microarray.
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Annotation term Total Found Expected P-value
GeneOntology terms
Globin 17 12 0.0E+00 0.0E+00
Rhodopsin-like receptor activity 384 49 3.8E 04 1.0E 06
G-protein chemoattractant receptor activity 34 8 2.8E 02 8.4E 04
Peptide receptor activity 139 23 1.7E 03 1.2E 05
G-protein-coupled receptor binding 52 21 0.0E+00 0.0E+00
Defense/immunity protein activity 230 39 0.0E+00 0.0E+00
Antimicrobial peptide activity 32 8 1.7E 02 5.4E 04
Complement activity 32 8 1.7E 02 5.4E 04
Signal transducer activity 2558 253 0.0E+00 0.0E+00
Receptor activity 1542 162 0.0E+00 0.0E+00
Transmembrane receptor activity 1083 121 0.0E+00 0.0E+00
G-protein coupled receptor activity 467 61 0.0E+00 0.0E+00
Chemokine receptor activity 34 8 2.8E 02 8.4E 04
Receptor binding 592 72 0.0E+00 0.0E+00
Cytokine activity 253 39 0.0E+00 0.0E+00
Heavy metal binding 23 8 9.4E 04 4.1E 05
Sugar binding 132 28 0.0E+00 0.0E+00
Extracellular 1085 138 0.0E+00 0.0E+00
Extracellular space 457 72 0.0E+00 0.0E+00
Hemoglobin complex 18 12 0.0E+00 0.0E+00
Plasma membrane 2297 219 0.0E+00 0.0E+00
Integral to plasma membrane 1702 176 0.0E+00 0.0E+00
Oxygen and reactive oxygen species metabolism 65 15 4.6E 04 7.0E 06
Calcium ion homeostasis 26 8 2.9E 03 1.1E 04
Cell motility 414 50 1.2E 03 3.0E 06
Chemotaxis 133 39 0.0E+00 0.0E+00
Muscle contraction 202 25 1.3E 01 6.2E 04
Response to stress 1025 143 0.0E+00 0.0E+00
Defense response 1031 169 0.0E+00 0.0E+00
Inflammatory response 218 50 0.0E+00 0.0E+00
Immune response 950 153 0.0E+00 0.0E+00
Humoral immune response 235 38 0.0E+00 0.0E+00
Antimicrobial humoral response (sensu Invertebrata) 145 24 1.2E 03 8.0E 06
Cellular defense response 139 45 0.0E+00 0.0E+00
Cell communication 3667 326 0.0E+00 0.0E+00
Cell adhesion 658 84 0.0E+00 0.0E+00
Heterophilic cell adhesion 97 20 9.7E 05 1.0E 06
Signal transduction 2947 254 0.0E+00 0.0E+00
Cell surface receptor linked signal transduction 1124 117 0.0E+00 0.0E+00
G-protein coupled receptor protein signaling pathway 657 77 0.0E+00 0.0E+00
Cytosolic calcium ion concentration elevation 49 10 3.2E 02 6.5E 04
Cell-cell signaling 689 64 3.7E 01 5.4E 04
Development 1920 150 1.5E+00 8.1E 04
Histogenesis and organogenesis 125 18 7.5E 02 6.0E 04
Muscle development 167 27 5.0E 04 3.0E 06
Respiratory gaseous exchange 36 11 2.2E 04 6.0E 06
Chemokine activity 52 21 0.0E+00 0.0E+00
Circulation 142 22 7.2E 03 5.1E 05
Peptide receptor activity/G-protein coupled 139 23 1.7E 03 1.2E 05
Response to external stimulus 1591 210 0.0E+00 0.0E+00
Response to biotic stimulus 1126 179 0.0E+00 0.0E+00
Response to wounding 356 91 0.0E+00 0.0E+00
Response to pest/pathogen/parasite 596 123 0.0E+00 0.0E+00
Response to bacteria 19 6 1.3E 02 7.1E 04
Response to abiotic stimulus 577 71 0.0E+00 0.0E+00
Morphogenesis 1119 101 4.9E 02 4.4E 05
Organogenesis 1029 91 2.2E 01 2.2E 04
Cellular process 7140 534 0.0E+00 0.0E+00
Membrane 4225 356 0.0E+00 0.0E+00
Integral to membrane 3220 281 0.0E+00 0.0E+00
Cell growth 97 17 7.3E 03 7.5E 05
Humoral defense mechanism (sensu Invertebrata) 145 24 1.2E 03 8.0E 06
Cell–cell adhesion 220 30 6.8E 03 3.1E 05
Antimicrobial humoral response 145 24 1.2E 03 8.0E 06
Cytolysis 20 8 2.4E 04 1.2E 05
Cytokine binding 80 14 2.6E 02 3.2E 04
Chemokine binding 34 8 2.8E 02 8.4E 04
Carbohydrate binding 133 28 0.0E+00 0.0E+00
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This study ﬁrst identiﬁed a large set of genes (MAD) showing
a 2-fold differential behavior in adenocarcinoma cells when
compared with normal lung tissue. Of these genes, 2528
genes (73.45%) were also identiﬁed passing the t-test criteria
(P < 0.005, complete t-test gene list available at http://
bioinfo.hku.hk/~daniely/lung_microarray/). Transcription
factors with binding site motifs that matched conserved
DNA regions upstream of genes in MAD were then identiﬁed,
asthesemay be the factorsthat regulate the oncogenic process.
This was achieved by incorporating both experimentally
determined gene expression data and bioinformatic tools.
Below, we will discuss the functional annotation groups
(gene ontology terms) that were overrepresented in the cancer
Table 2. Continued
Annotation term Total Found Expected P-value
Chemoattractant activity 52 21 0.0E+00 0.0E+00
Response to chemical substance 206 48 0.0E+00 0.0E+00
Peptide binding 213 26 1.3E 01 6.1E 04
Taxis 133 39 0.0E+00 0.0E+00
Chemokine receptor binding 52 21 0.0E+00 0.0E+00
Innate immune response 220 50 0.0E+00 0.0E+00
Eicosanoid biosynthesis 25 7 1.4E 02 5.7E 04
Protein domain
Vertebrate metallothionein 12 7 2.4E 05 2.0E 06
Aspartic acid and asparagine hydroxylation site 143 21 3.5E 02 2.5E 04
Rhodopsin-like GPCR superfamily 289 42 0.0E+00 0.0E+00
Endothelin receptor 6 4 1.3E 03 2.1E 04
Small chemokine, C-C subfamily 26 11 0.0E+00 0.0E+00
Fos transforming protein 13 6 9.5E 04 7.3E 05
Thrombospondin, type I 52 13 7.8E 04 1.5E 05
Globin 16 12 0.0E+00 0.0E+00
Small chemokine, C-X-C subfamily 18 6 1.1E 02 6.0E 04
C-type lectin 95 19 5.7E 04 6.0E 06
Alpha crystallin 8 4 7.2E 03 9.0E 04
Myelin proteolipid protein (PLP) 7 6 0.0E+00 0.0E+00
Zn-binding protein, LIM 95 18 2.2E 03 2.3E 05
Small chemokine, interleukin-8 like 48 20 0.0E+00 0.0E+00
EGF-like calcium-binding 147 21 5.3E 02 3.6E 04
Heat shock protein Hsp20 8 4 7.2E 03 9.0E 04
Fibrinogen, beta/gamma chain, C-terminal globular 38 10 3.4E 03 8.9E 05
P2 purinoceptor 21 7 4.3E 03 2.1E 04
Myoglobin 9 6 3.6E 05 4.0E 06
Beta haemoglobin 8 7 0.0E+00 0.0E+00
Alpha haemoglobin 6 5 3.6E 05 6.0E 06
Pi haemoglobin 6 5 3.6E 05 6.0E 06
Small chemokine, C-X-C/Interleukin 8 18 8 1.1E 04 6.0E 06
Metallothionein superfamily 12 7 2.4E 05 2.0E 06
Orphan nuclear receptor 9 5 9.1E 04 1.0E 04
Immunoglobulin C-2 type 223 31 6.2E 03 2.8E 05
Immunoglobulin subtype 368 48 3.7E 04 1.0E 06
PMP-22/EMP/MP20 family 8 4 7.2E 03 9.0E 04
L1 transposable element 8 4 7.2E 03 9.0E 04
EGF-like domain 431 46 1.4E 01 3.3E 04
Type I EGF 169 23 6.7E 02 4.0E 04
AIG1 family 6 4 1.3E 03 2.1E 04
BRICHOS domain 13 8 0.0E+00 0.0E+00
Immunoglobulin-like 678 75 6.8E 04 1.0E 06
LST-1 6 6 0.0E+00 0.0E+00
Thrombospondin, subtype 1 27 8 5.0E 03 1.8E 04
Saposin-like type B, 2 7 5 1.3E 04 1.9E 05
Saposin B 12 5 6.5E 03 5.4E 04
Pathway
GPCRs_Class_A_Rhodopsin-like 212 34 0.0E+00 0.0E+00
Peptide_GPCRs 88 20 0.0E+00 0.0E+00
MAP00590//Prostaglandin and leukotriene metabolism 41 9 3.2E 02 7.7E 04
GPCRs_Class_B_Secretin-like 34 10 9.2E 04 2.7E 05
Chromosomal location
12p 301 32 2.4E 01 8.1E 04
8p21 117 18 1.8E 02 1.5E 04
17q23 68 14 2.2E 03 3.2E 05
16q13 37 12 3.7E 05 1.0E 06
Foreachgeneontologyterm,thetotalnumberofgeneswiththistermintheHG-U133AGeneChip,thetotalnumberofgenescarryingthatterminMAD,theP-valueof
this and the expected number of genes are tabulated. The member genes for each gene ontology term can be downloaded at http://bioinfo.hku.hk/~daniely/
lung_microarray.
Nucleic Acids Research, 2005, Vol. 33, No. 1 415Table 3. The gene ontology terms overrepresented in the set of genes up-regulated by at least 2-fold in adenocarcinomas
Annotation term Total Found Expected P-value
Gene Ontology term
DNA replication and chromosome cycle 233 54 0.0E+00 0.0E+00
Cell cycle checkpoint 50 17 5.5E 04 1.1E 05
S phase of mitotic cell cycle 183 38 1.1E 02 6.1E 05
M phase of mitotic cell cycle 149 46 0.0E+00 0.0E+00
Nucleotide binding 1737 235 2.1E 01 1.2E 04
Mitotic cell cycle 421 97 0.0E+00 0.0E+00
M phase 201 52 0.0E+00 0.0E+00
Nuclear division 195 50 0.0E+00 0.0E+00
Chromatin 117 29 1.8E 03 1.5E 05
Nucleosome 60 16 3.0E 02 5.0E 04
Cytokinesis 85 24 6.8E 04 8.0E 06
Catalytic activity 4887 638 0.0E+00 0.0E+00
Carboxypeptidase A activity 18 8 5.5E 03 3.1E 04
Extracellular matrix structural constituent 89 21 4.0E 02 4.5E 04
Collagen 54 23 0.0E+00 0.0E+00
ATP binding 1280 177 4.0E 01 3.1E 04
Extracellular matrix 345 65 2.1E 03 6.0E 06
Collagen 59 24 0.0E+00 0.0E+00
Fibrillar collagen 23 14 0.0E+00 0.0E+00
Chromosome 147 32 1.3E 02 8.8E 05
Spindle 64 21 1.3E 04 2.0E 06
Intermediate filament 76 19 2.9E 02 3.8E 04
DNA metabolism 606 97 3.1E 02 5.1E 05
DNA replication 178 36 2.9E 02 1.6E 04
DNA dependent DNA replication 94 23 1.3E 02 1.4E 04
DNA replication initiation 25 11 6.3E 04 2.5E 05
Amino acid and derivative metabolism 240 54 0.0E+00 0.0E+00
Amino acid metabolism 197 43 1.2E 03 6.0E 06
Oncogenesis 521 84 6.6E 02 1.3E 04
Cell cycle 871 145 0.0E+00 0.0E+00
Chromosome segregation 35 11 2.9E 02 8.4E 04
Mitosis 145 45 0.0E+00 0.0E+00
Regulation of mitosis 35 12 6.9E 03 2.0E 04
Mitotic checkpoint 16 7 1.3E 02 8.3E 04
Ectoderm development 98 26 1.1E 03 1.1E 05
Cell proliferation 1356 190 1.2E 01 8.9E 05
Epidermal differentiation 80 22 2.2E 03 2.8E 05
Glutamine family amino acid metabolism 46 15 2.9E 03 6.3E 05
Amine metabolism 283 60 0.0E+00 0.0E+00
Histogenesis 131 28 4.3E 02 3.3E 04
Glucuronosyltransferase activity 18 8 5.5E 03 3.1E 04
Transferase activity 1634 224 1.3E 01 8.1E 05
Transferase activitytransferring glycosyl groups 225 42 7.0E 02 3.1E 04
Transferase activitytransferring hexosyl groups 148 34 2.5E 03 1.7E 05
Other carbon–nitrogen ligase activity 25 9 2.1E 02 8.3E 04
Purine nucleotide binding 1723 233 2.3E 01 1.4E 04
Adenyl nucleotide binding 1292 179 3.4E 01 2.6E 04
Intermediate filament cytoskeleton 76 19 2.9E 02 3.8E 04
Protein domain
Fibrillar collagen, C-terminal 23 14 0.0E+00 0.0E+00
Endoplasmic reticulum targeting sequence 76 19 2.0E 02 2.6E 04
Epsin N-terminal homology 16 7 1.1E 02 6.9E 04
MCM family 11 8 2.2E 05 2.0E 06
Prolyl oligopeptidase 12 6 8.6E 03 7.1E 04
Intermediate filament protein 67 17 3.0E 02 4.4E 04
von Willebrand factor, type D 9 6 7.7E 04 8.6E 05
UDP-glucoronosyl/UDP-glucosyl transferase 15 7 6.4E 03 4.3E 04
Prolyl endopeptidase, serine active site 8 5 4.4E 03 5.5E 04
Immunoglobulin V-type 146 32 6.3E 03 4.3E 05
Cyclin, C-terminal 19 9 1.0E 03 5.4E 05
Disulphide isomerase 12 7 8.4E 04 7.0E 05
Cyclin 44 14 4.7E 03 1.1E 04
Cyclin, N-terminal domain 34 12 3.7E 03 1.1E 04
Histone core 25 9 1.7E 02 6.7E 04
Collagen triple helix repeat 106 28 3.2E 04 3.0E 06
Collagen helix repeat 69 22 6.9E 05 1.0E 06
416 Nucleic Acids Research, 2005, Vol. 33, No. 1associated genes and their putative regulatory transcription
factors. Only some salient ﬁndings can be presented due to
the size of the dataset and full details are provided as Supple-
mentary Material.
In a separate study, we identiﬁed 88 lung cancer associated
genes (data not shown) from our microarrays, using a feature
partitioning method we developed earlier (37). However, here,
we aimed to identify the broadest set of cancer associated
genes (MAD) by using fold-ratio analysis, and to examine
their functional annotations in order to understand the biolo-
gical processes that are altered in cancer when compared with
normal tissue. A broad gene set was important to ensure stat-
istical validity when determining the functional groups (gene
ontology terms) that were overrepresented in the gene popula-
tion in MAD. More than three thousand genes were found to be
up- or down-regulated by >2-fold and all 88 cancer associated
genes identiﬁed using the earlier method (37) were found
in this set.
In previous works (38–40), differential gene expression
in cancer was reported but relatively little elaboration of the
genes’functions,ortheregulatorycascadesandbiologicalpro-
cesses underlying the observations was made. Here, we found
that many gene ontology terms disproportionately occurred
(P < 0.001) among the sets of genes that were either substant-
ially up- or down-regulated in adenocarcinomas. This gave
evidence of the systematic up- or down-regulation of several
biological processes directly linked to oncogenesis. Such pro-
cesses included increased cell multiplication, angiogenesis,
vascularization, and glucose and amino acid metabolism.
Glucose metabolism is crucial because cancer cell growth
depends on glucose availability, rather than respiration, for
biomass construction (41). Increased expression of glycolytic
enzymes, including pyruvate carboxylase, citrate synthase,
aconitate hydratase, oxalosuccinate decarboxylase, glucose-
6-phosphate isomerase, fructose-bisphosphate aldolase, gluc-
ose transporter (GLUT) and L-lactate dehydrogenase were
observed in the microarray data. This is consistent with the
fermentation metabolism (needed for ATP synthesis in the
absence of efﬁcient respiration), and with entry into a tricar-
boxylic acid pathway for glutamate and aspartate synthesis
(i.e. biomass construction) rather than respiration.
Unlike mostly resting normal cells, where oxygen is used in
oxidative phosphorylation for ATP synthesis and cell main-
tenance, cancer cells metabolize glucose at a much higher rate,
in order to generate ATP and use pyruvate as the substrate to
generate lactate to replete the NAD pool (Warburg’s effect),
while stopping the cycling of the tricarboxylic acid pathway
(42,43). The major outcome of this metabolic shift is, by
preventing the tricarboxylic acid pathway cycling, to produce
biomass rather than energy. This effect, overlooked for some
time, was discovered >70 years ago (41). Much effort has been
initiated to identify the transcription factor(s) that facilitate
thischangeofcourseincancer cells(fromaerobicslowgrowth
or resting state into anaerobic use of glucose while growing)
by up-regulating the expression and activity of all enzymes
directly related to this essential metabolic pathway. In recent
publications, several transcription factors [hypoxia inducible
factor 1 (HIF-1) (44); Myc (45); Ras (46); v-SRC(47); p53(48)
and pVHL(49)] were reported to play a role in the regulation
of the expression of these glycolytic enzymes.
From the genes in MAD associated with each over-
represented gene ontology term, a subset of genes with more
consistent expression proﬁles was identiﬁed and the upstream
regions of these genes were searched for conserved elements.
Such conserved DNA regions, if they exist, are likely to be
evolutionarily signiﬁcant (50–54). Wasserman et al. (55)
showed that a large proportion (>98%) of experimentally
deﬁned transcription factor binding sites are restricted to the
most conserved residues within their own promoter regions.
Earlier studies have used databases such as TRANSFAC to
search for transcription factor binding sites in the upstream
regions of genes; however, this can lead to many false
positives (56,57). Clustering of genes based on expression
proﬁles has been used to select sets of genes more likely to be
co-regulated (20); however, with increasing numbers of genes
in the clusters, the number of false positive identiﬁcations
increases. One reason for this is the inclusion of genes
in the cluster that are not actually co-regulated, hampering
the correct detection of conserved DNA regions by most
motif discovery tools (21,22). Methods to evaluate putative
regulatory sites and newly detected motifs have also been
proposed (58).
To address this issue, we combined the gene expression
correlation coefﬁcients and gene functional classes of all
the cancer-associated genes (MAD) to select a more consistent
set of likely co-regulated genes. These genes not only had a
consistent expression pattern with the highest possible pair-
wise gene correlation, but also shared the same functional
role. No limit was placed on the number of genes that
would be selected from each functional group, and all
genes with expression proﬁles within a cutoff value (d < 0.20)
were selected. These criteria were motivated by there being
Table 3. Continued
Annotation term Total Found Expected P-value
Pathway
Cell_cycle 133 43 5.7E+00 4.3E 02
Glutamate_metabolism 27 12 3.2E 01 1.2E 02
MAP00251//glutamate metabolism 43 15 6.5E 01 1.5E 02
Androgen_and_estrogen_metabolism 15 7 1.1E 01 7.0E 03
MAP00150//androgen and estrogen metabolism 32 11 3.5E 01 1.1E 02
Chromosomal location
7 961 129 8.7E 01 9.1E 04
1q 920 126 4.4E 01 4.8E 04
8q 388 67 5.8E 03 1.5E 05
Details are as described in Table 2.
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418 Nucleic Acids Research, 2005, Vol. 33, No. 1many examples, which show that transcription factors have
multiple target genes, of which a signiﬁcant portion is
involved in a common metabolic pathway. For instance, the
CAP transcription factor in Escherichia coli has been shown
to mediate the regulation of dozens of genes involved in
glucose metabolism (59,60). In humans, the GATA binding
protein 1 (globin transcription factor 1, GATA-1) plays an
important role in erythroid development by regulating hemo-
globin production (61). The majority of genes that are regu-
lated by this transcription factor contain the gene ontology
term ‘hemoglobin’. Moreover, growth factor independent 1
(Gﬁ-1) acts on a subset of genes involved in the differentia-
tion of the hematopoietic lineage (62).
MoDEL, the motif discovery program used here, has been
demonstrated extensively and compared with other existing
motif ﬁnding algorithms by analyzing sets of complex natural
amino acid sequences (e.g. HTH protein motifs) and artiﬁcial
datasets (planted motifs) (26). It was shown to have a more
efﬁcient optimization method than other local multiple align-
ment methods. Unlike algorithms that search for motifs by
exhaustive enumeration of overrepresented words (63),
MoDEL looks for a set of conserved occurrences based
on information content (26). The objective of MoDEL is to
identify exactly one occurrence per sequence in such a way
that all chosen occurrences are maximally similar across the
sequence set. A validation of MoDEL on the CAP-mediated
gene set (59) in bacteria successfully extracted the conserved
regions that incorporate the CAP binding sites (Supplementary
Material).
Having identiﬁed conserved DNA regions associated with
genes with the same functional annotation and similar
expression proﬁles, in silico pattern-based scanning against
the TRANSFAC 8.3 database for transcription factors with
binding site motifs in these conserved DNA regions was per-
formed. Among the transcription factors identiﬁed as putative
regulatory factors for these genes (Table 4), some had been
reported in previous publications to promote or suppress
cancer formation, whereas the remaining transcription factors
have generallynotbeen sufﬁciently characterized invivo. Four
of these appear to be particularly signiﬁcant, namely: HIF-1,
Gﬁ-1, nuclear factor TG-interacting factor (TGIF) and
erythroid transcription factor (GATA-1).
HIF-1 is a regulatory heterodimer consisting of two sub-
units; HIF-1b is constitutively expressed in all conditions,
whereas HIF-1a is rapidly degraded under normal conditions
but is stabilized under hypoxia (64). Despite an average up-
regulation of this protein (HIF-1a)b y 30% in our dataset,
ourinitialscreeningfor cancer gene markersdidnotreveal this
protein because the expression change was too small to be
selected. From our microarray ﬁndings, the up-regulation of
this protein did not result in a systematic activation of gene
clusters with a speciﬁc function. However, the fact that
HIF-1 binding sites were found to be enriched in some
down-regulated genes that belonged to the cellular defense
response gene ontology term (Table 4), suggested that this
protein might be one of the cellular components responsible
for the suppression of the defense response of hypoxic cancer
cells. Other genes related to growth factor, protease and apop-
tosispathways,e.g.epidermal growthfactor receptor, carbonic
anhydrase IX, p53-, matrix metalloproteinase 9, that were
known to be dependent on HIF-1a for their activation (65)
had fold changes of 2.41, 2.8, 6.5 and 2.51, respectively, in our
dataset.
Gﬁ-1 is a zinc ﬁnger protein that binds DNA and functions
as a transcriptional repressor through its unique repressor
domain, SNAG (66). In our arrays, this gene was down-
regulated in adenocarcinoma cells by an average of 69%,
and it was observed that genes that contain activation sites
for Gﬁ-1 were mostly up-regulated in adenocarcinoma cells.
One example is the pro-apoptotic regulator gene Bax which
was up-regulated by 2.3-fold in adenocarcinoma cells but was
shown to be down-regulated by Gﬁ-1 in immortalized T-cell
lines and primary transgenic thymocytes (67).
TGIF is a transcriptional core-repressor that directly associ-
ates with Smad (Sma- and Mad-related protein) proteins and
inhibits Smad-mediated transcriptional activation (68). The
gene responses activated by Smad underlie both proliferative
and anti-proliferative events that contribute to cancer (69,70).
Originally, TGIF was isolated as a ubiquitously expressed
homeodomain protein that can bind to the retinoid X receptor
(RXR) response element (71). Based on our analysis, this gene
was up-regulated in lung cancer cells by an average of 2.6-
fold while the RXR gene was repressed by an average of 25%.
GATA-1 is a factor that had been shown to be important in
the regulation of globin and non-globin genes in erythroid,
megakaryocytic and mast cell lineages (72). From our arrays,
this gene was down-regulated by an average of  40% in
cancer cells. This is consistent with our ﬁndings that members
in globin gene family (a, b and g) were all repressed in ade-
nocarcinomas, despite their weak association with primary
lung cancers (Table 2).
In conclusion, by investigating the statistical distribution of
the functional annotations attached to cancer associated genes
(MAD) derived from lung tissue microarrays, we have identi-
ﬁed functions, corresponding to several key biological sys-
tems, which are overrepresented in cancer associated genes
(Tables 2 and 3). The congruence of these functions with
known cancer cell oncogenic processes suggests the up- or
down-regulation of genes in MAD is linked to cancer-related
metabolismprocesses.Subsequently, we clusteredthe genesin
MAD into putatively co-regulated gene sets by assuming that
co-regulated genes will share common functional roles and
exhibit very similar expression proﬁles. Conserved DNA seg-
ments in the upstream regions of these putatively co-regulated
gene sets were found and transcription factors that recognize
these DNA regions were identiﬁed (Table 4). A literature
search on these transcription factors, which are putative reg-
ulatory factors in adenocarcinoma development, substantiated
that themajority hadbeen previouslydocumentedexperiment-
ally to be oncogenic transcription factors. These transcription
factors, together with their conserved binding sites, suggest
new candidates for therapeutic intervention in the treatment of
lung adenocarcinomas.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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